Atomoxetine Capsules Recalled for N-Nitroso Impurity Above FDA Limits
Glenmark Pharmaceuticals is recalling Atomoxetine capsules due to N-Nitroso impurity levels exceeding FDA recommended limits. The recall affects 56,208 bottles nationwide with specific lot numbers.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall for N-Nitroso impurity above FDA recommended limits. N-nitroso compounds are known health hazards with potential genotoxic properties. This qualifies as a risk-of-harm product without reported adverse events.
Plain-English summary
Glenmark Pharmaceuticals Inc., USA is recalling Atomoxetine Capsules, USP, 18 mg, nationwide due to current Good Manufacturing Practice (CGMP) deviations. The recalled product contains N-Nitroso Atomoxetine impurity at levels above FDA recommended limits.
The recall affects 56,208 bottles distributed nationwide. Affected lot numbers include 19233756 (expiration 8/2025), 19235111 (expiration 11/2025), 19242167 (expiration 5/2026), and 19242180 (expiration 5/2026). The product is identified by NDC 68462-266-30 and related package NDCs.
Consumers and healthcare providers with affected bottles should contact their healthcare provider or pharmacist before discontinuing the medication. Patients should not stop taking their medication without medical guidance.
The recalled product
- Product
- ATOMOXETINE (ATOMOXETINE)
- Brand
- ATOMOXETINE
- Manufacturer
- Glenmark Pharmaceuticals Inc., USA
- Category
- Drug
- Affected units
- 56,208
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (8)
- Lot Numbers: 19233756
- Exp.: 8/2025
- 19235111
- Exp.: 11/2025
- 19242167
- Exp.: 5/2026
- 19242180
- Exp.: 5/2026.
UPCs (7)
- 0368462265307
- 0368462270301
- 0368462267301
- 0368462271308
- 0368462268308
- 0368462269305
- 0368462266304
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 14 recalled by Glenmark Pharmaceuticals Inc., USA under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 14 products in this recall →Related recalls
Same brand · ATOMOXETINE
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- HighAtomoxetine Capsules Recalled for Elevated Nitrosamine Impurity
FDA (Drugs) · 2025-02-26
- HighAtomoxetine Capsules Recalled Due to Excess N-Nitroso Impurity
FDA (Drugs) · 2025-02-26
- HighAtomoxetine Capsules Recalled Nationwide for N-Nitroso Impurity Exceeding FDA Limits
FDA (Drugs) · 2025-02-26
- HighAtomoxetine 80 mg Capsules Recalled for N-Nitroso Impurity Contamination
FDA (Drugs) · 2025-02-26
Same manufacturer · Glenmark Pharmaceuticals Inc., USA
See all →- ModerateAzelaic Acid Gel 15% Recalled Over Grainy, Gritty, or Sandy Texture
FDA (Drugs) · 2026-08-05
- ModerateAlyacen 7/7/7 birth control tablets failed total impurities specification
FDA (Drugs) · 2026-06-24
- ModerateOndansetron tablets recalled because blister packs are not fully sealed
FDA (Drugs) · 2026-01-07
- CriticalFrozen chopped methi recalled after testing positive for Salmonella
FDA (Drugs) · 2025-12-17
- ModerateBisoprolol and hydrochlorothiazide tablets recalled over traces of another drug
FDA (Drugs) · 2025-12-10
Same hazard · impurity
See all →- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateMedline Remedy Specialized Silicone Cream Recalled for Elevated Formaldehyde Levels
FDA (Drugs) · 2026-07-15
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17